To include your compound in the COVID-19 Resource Center, submit it here.

Acorda discloses safety concerns for PD candidate tozadenant

Acorda Therapeutics Inc. (NASDAQ:ACOR) disclosed cases of agranulocytosis that were possibly related to treatment with Parkinson's disease candidate tozadenant (SYN115) and in some cases associated with sepsis and death.

Among about 890 patients who received the selective adenosine A2A

Read the full 387 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE